<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:inherit;
panose-1:0 0 0 0 0 0 0 0 0 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below for a survey from CCSN.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>If it applies to you, plse participate.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Thx.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> CCSN Communications [mailto:communications@survivornet.ca] <br><b>Sent:</b> August 8, 2019 10:52 AM<br><b>To:</b> undisclosed-recipients:<br><b>Subject:</b> Patient Survey Distribution<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt'><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:black;font-weight:normal'>Hello,</span><span style='font-weight:normal'><o:p></o:p></span></h1><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt'><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:black;font-weight:normal'>The CCSN has created a survey for the new prostate cancer drug darolutamide. We ask for your help in its distribution. They survey will be open until August 30. The purpose of the survey is to provide insights and perspectives about living with and managing prostate cancer from patients and caregivers in order to complete a patient evidence submission for a new medication for non-metastatic castration-resistant prostate cancer. I have included the text that is posted on our website. Please feel free to use the text. The title and "find survey here" line are hyperlinked already.</span><span style='font-weight:normal'><o:p></o:p></span></h1></div><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;mso-line-height-alt:19.5pt'><span style='font-weight:normal'><o:p> </o:p></span></h1></div><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt'><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:black;font-weight:normal'>This is the survey link: </span><span style='font-size:12.0pt;font-weight:normal'><a href="https://www.surveymonkey.com/r/XQJ8TGW">https://www.surveymonkey.com/r/XQJ8TGW</a></span><span style='font-weight:normal'><o:p></o:p></span></h1></div><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;mso-line-height-alt:19.5pt'><span style='font-weight:normal'><o:p> </o:p></span></h1></div><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt'><span style='font-size:12.0pt;font-weight:normal'>Thank you for your help!</span><span style='font-weight:normal'><o:p></o:p></span></h1></div><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt'><span style='font-size:12.0pt;font-weight:normal'>Siobhan Morgulis</span><span style='font-weight:normal'><o:p></o:p></span></h1></div><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt'><span style='font-size:12.0pt;font-family:"inherit","serif";color:#222222;font-weight:normal'><o:p> </o:p></span></h1></div><div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt'><span style='font-size:12.0pt;font-family:"inherit","serif";color:#222222;font-weight:normal'><o:p> </o:p></span></h1></div><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt;box-sizing:inherit;display:inline-block'><span style='font-size:18.0pt;font-family:"inherit","serif";color:#0D3C50;font-weight:normal'><o:p> </o:p></span></h1><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt;box-sizing:inherit;display:inline-block'><span style='font-size:18.0pt;font-family:"inherit","serif";color:#0D3C50;font-weight:normal'><o:p> </o:p></span></h1><h1 style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:2.25pt;margin-left:0cm;line-height:19.5pt;box-sizing:inherit;display:inline-block'><span style='font-size:18.0pt;font-family:"inherit","serif";color:#0D3C50;font-weight:normal'><a href="https://www.surveymonkey.com/r/XQJ8TGW">Prostate Cancer Patients & Caregivers: Help Shape the Future of Medicine</a><o:p></o:p></span></h1><div><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm'><span style='font-size:11.5pt;font-family:"Arial","sans-serif";color:#333333'>If you are a prostate cancer patient or caregiver who has perspectives on darolutamide, CCSN wants your feedback. We are looking to hear primarily from non-metastatic castration-resistant prostate cancer patients and their caregivers. However, if you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;box-sizing:inherit'><span style='font-size:11.5pt;font-family:"Arial","sans-serif";color:#333333'>Clinical trials help to shape the future of medicine. You are a vital part of the drug approval process. Your experiences will help pave the way for new and improved treatments for other prostate cancer patients. We kindly ask that you share your experiences with us in this survey.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;box-sizing:inherit'><span style='font-size:11.5pt;font-family:"Arial","sans-serif";color:#333333'>Your voice in the process to find new and improved treatments and cures is what matters most in advancing new standards. You can share your unique perspective and be heard by answering this survey, which will inform the Canadian legislature boards of your personal experiences.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;box-sizing:inherit'><span style='font-size:11.5pt;font-family:"Arial","sans-serif";color:#333333'>By providing us with your input, you are making a valuable contribution to the future of cancer treatments. CCSN values your time and opinions.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;box-sizing:inherit'><span style='font-size:11.5pt;font-family:"Arial","sans-serif";color:#333333'>The survey will remain open until August 30th, 2019.<o:p></o:p></span></p><p style='mso-margin-top-alt:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;box-sizing:inherit'><span style='font-size:11.5pt;font-family:"Arial","sans-serif";color:#333333'><a href="https://www.surveymonkey.com/r/XQJ8TGW"><b><span style='font-size:13.5pt;font-family:"inherit","serif"'>Find the survey here.</span></b></a><o:p></o:p></span></p></div><div><p class=MsoNormal><o:p> </o:p></p></div><p class=MsoNormal>-- <o:p></o:p></p><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><p class=MsoNormal><b><span style='font-size:9.5pt'>Communications and Social Media Coordinator</span></b><span style='font-size:9.5pt'><o:p></o:p></span></p></div><div><p class=MsoNormal><b><span style='font-size:9.5pt'>Coordonnatrice, Communications et médias sociaux</span></b><span style='font-size:9.5pt'><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.5pt'>Canadian Cancer Survivor Network<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.5pt'>Réseau canadien des survivants du cancer<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.5pt'>1750 croissant Courtwood Crescent, Suite 210<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.5pt'>Ottawa, ON K2C 2B5<o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.5pt'>Telephone / Téléphone : <a href="tel:613-898-1871" target="_blank"><span style='color:#1155CC'>613-898-1871</span></a><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.5pt'>E-mail / Courriel : <a href="mailto:communications@survivornet.ca" target="_blank">communications<span style='color:#1155CC'>@survivornet.ca</span></a><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.5pt'>Web site / site web: <a href="http://www.survivornet.ca/" target="_blank"><span style='color:#1155CC'>www.survivornet.ca</span></a><o:p></o:p></span></p></div><div><p class=MsoNormal><span style='font-size:9.5pt'>Twitter: @</span><a href="http://www.twitter.com/survivornetca" target="_blank"><span style='font-size:9.5pt;color:#1155CC'>survivornet</span><span style='font-size:9.5pt'>ca</span></a><o:p></o:p></p><div><div><div><div><div><div><p class=MsoNormal><span style='font-size:9.5pt'>----------------------------------------------------------<o:p></o:p></span></p></div><div><div><p class=MsoNormal><a href="https://www.32auctions.com/ccsnchangecancer" target="_blank"><span style='color:#1155CC;text-decoration:none'><img border=0 width=420 height=210 id="_x0000_i1025" src="https://docs.google.com/uc?export=download&id=14UMVLGB-4bRpqcZ3FrNVb_YDuRL-8v1M&revid=0B3eZvSHPg97rVlMrU0Nrb2NwbVhtRldPL0JXYVhMRGN5RlVJPQ"></span></a><o:p></o:p></p></div><div><p class=MsoNormal><a href="https://www.32auctions.com/ccsnchangecancer" target="_blank"><span style='color:#1155CC'>Support survivorship.</span></a><o:p></o:p></p></div><div><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto'><a href="https://www.32auctions.com/ccsnchangecancer" target="_blank"><span style='color:#1155CC'>Participate in our Online Change Cancer Auction</span></a><o:p></o:p></p><p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto'><a href="https://mailchi.mp/survivornet/eletter-signup" target="_blank"><span style='color:#1155CC'>Sign Up for our newsletter.</span></a><o:p></o:p></p></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></body></html>